Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07738237

Clinical Evaluation of Hearing Aid OTC Self-Assessment Methods for Adults With Perceived Mild-to-Moderate Hearing Loss

The goal of this clinical trial is to compare two methods of self assessment of hearing with conventional audiometry in an OTC Hearing Aid for adults with perceived mild to moderate hearing loss. The main questions it aims to answer are:

1. To evaluate agreement between prescribed gain outputs generated from conventional audiometry and those generated from the self-assessment response method. 2. Determine whether either self-assessment response method provides acceptable estimated audibility. 3. Evaluate participant preference between the detection response method and the audibility-release response method.

Researchers will compare the two novel methods with conventional audiometry to determine levels of agreement.

Participants will self assess their hearing methods using two novel methods of hearing assessment as well as receive a conventional audiometric evaluation of hearing levels.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

The purpose of this clinical investigation is to evaluate two RH210 hearing aid software self-assessment response methods used to generate NAL-R-based prescribed gain for adults with perceived mild-to-moderate hearing loss. The study will compare prescribed gain outputs derived from each RH210 self-assessment response method with prescribed gain outputs derived from conventional audiometry using the same NAL-R prescription approach. The study will also assess whether the resulting prescribed gain provides estimated audibility using Speech Intelligibility Index (SII) analysis, and will evaluate participant preference between the two self-assessment response methods. The RH210A is an air-conduction hearing aid designed for adults with perceived mild-to-moderate sensorineural hearing loss.

The two RH210 self-assessment response methods evaluated in this study are:

  • Detection response method (Option 1): the participant presses a response control when they hear the tone or beep.
  • Audibility-release response method (Option 2): the participant maintains a press while the tone or beep is audible and releases the response control when they no longer hear it.

The study is designed to:

  • Evaluate agreement between NAL-R prescribed gain outputs generated from conventional audiometry and NAL-R prescribed gain outputs generated from each RH210 self-assessment response method.
  • Compare the detection response method and audibility-release response method with respect to prescribed gain agreement by ear and frequency.
  • Assess estimated audibility associated with the self-assessment-derived NAL-R prescriptions using Speech Intelligibility Index (SII) analysis.
  • Determine whether either self-assessment response method provides acceptable estimated audibility, including in cases where prescribed gain does not exactly match the conventional-audiometry-derived NAL-R prescription.
  • Evaluate participant preference between the detection response method and the audibility-release response method.
  • Assess general agreement, completeness, invalid-test rate, usability and response consistency for each self-assessment response method.
  • Support validation of the Rehear assessment-to-fitting pathway without positioning the RH210 self-assessment function as a diagnostic audiometer.

This study is not intended to establish Human Factors performance. However, observations arising during execution of the assessment workflow may identify opportunities to improve the user interface, workflow or user guidance before the final Human Factors validation study. These observations are exploratory development outputs and are not formal study endpoints.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years
  • Self-perceived mild-to-moderate hearing difficulties/ hearing loss
  • Competent smartphone use (able to complete self-fitting via the app)
  • Able and willing to provide informed consent
  • HHIA screening consistent with perceived hearing difficulty
  • Willingness and ability to attend two in-person research appointments
  • Ability to operate a SmartPhone

Exclusion criteria

  • Conductive or mixed hearing loss
  • Occluding cerumen
  • Otologic disease/ active ear pathology
  • Severe or profound hearing loss (PTA >S0dBHL) (WHO, 2021)
  • Presence of (red-flag) conditions relevant to OTC hearing aid use (per 21 CFR 801.421)
  • Visible deformity of the ear (congenital or traumatic).
  • Fluid, pus, or blood coming from the ear (e.g., active drainage).
  • Sudden or rapidly progressive hearing loss within the recent past (often defined as within ~90 days).
  • Any acute or chronic dizziness or vertigo associated with hearing issues.
  • Pain or discomfort in or around the ear.
  • Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
  • Unilateral hearing loss of sudden onset or large asymmetry between ears.
  • Audiometric air-bone gap suggestive of possible conductive pathology (e.g., gap equal or more than 15 dB at key frequencies)
  • Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
  • Unilateral hearing loss of sudden onset or large asymmetry between ears

Exclusion criteria

-

Treatment and study plan

OTC Hearing Aid Self Fitting App

Device

The Investigational Medical Device (IMD) consists of the RH210 hearing aid software self-test function accessed through the Rehear smartphone application and used in combination with the RH210A compatible in-ear hardware platform.

For this clinical investigation, the RH210A hardware platform is used to present calibrated test sounds (pure tones) to the participant during the app-based self-test. The RH210A is not being evaluated as a diagnostic audiometer, and the study is not designed to evaluate the hearing aid's amplification performance.

The two RH210 self-test response methods evaluated in this study are:

  • Detection response method: the participant presses the response control when they hear the tone or beep (Mode A).
  • Audibility-release response method: the participant maintains the response control while the tone or beep is audible and releases the response control when they no longer hear the tone or beep (Mode B).

Audiometry

Procedure

The comparator for this clinical investigation is conventional manual pure-tone audiometry performed in accordance with ANSI/ASA S3.21-2004 (R2023), Methods for Manual Pure-Tone Threshold Audiometry, followed by generation of a NAL-R-based prescribed gain output.

Primary outcomes

  1. Agreement of NAL-R prescribed gain outputs between the comparator conditions

    Time frame: Day 1

    The primary endpoint is the agreement of NAL-R prescribed gain outputs, by ear and frequency, between:

    • Conventional-audiometry-derived NAL-R prescribed gain, and
    • RH210 self-test-derived NAL-R prescribed gain, generated using each of the two RH210 response methods.

    The frequency-specific analysis will include: 500 Hz; 1 kHz; 2 kHz; and 4 kHz.

    The two RH210 response methods are:

    • Detection response method: participant presses when they hear the tone or beep (Mode A).
    • Audibility-release response method: participant releases the response control when they no longer hear the tone or beep Mode B).

Secondary outcomes

  1. Difference in Speech Intelligibility Index (SII) and SRT in quiet (CNC words) between the three conditions

    Time frame: Day 1

    The secondary objective is to evaluate whether RH210 self-test-derived NAL-R prescribed gain outputs provide estimated audibility comparable to the conventional-audiometry-derived NAL-R reference pathway.

    The secondary endpoint is the difference in Speech Intelligibility Index / Audibility Index and SRT in quiet between:

    • The conventional-audiometry-derived NAL-R prescribed gain condition; and Page 15 of 40 OFFICIAL
    • Each RH210 self-test-derived NAL-R prescribed gain condition. The analysis will be conducted under a pre-specified standard aided speech condition, for example adaptive speech in quiet SRT50, with the final method defined in the Statistical Analysis Plan
  2. Number of Participants with Treatment-Related Adverse Events as classified by ISO14155:2026

    Time frame: Day 1

    The secondary safety objective is to assess the safety of participant exposure to the RH210 app-based self-test procedure when the RH210A in-ear hardware platform is used to present test sounds.

    Safety will be assessed by the incidence, severity, seriousness and relationship to the investigational device or study procedure of:

    • adverse events;
    • adverse device effects;
    • anticipated adverse device effects;
    • discomfort associated with in-ear device use;
    • excessive loudness or sound intolerance;

    No formal statistical hypothesis is proposed for safety. Safety outcomes will be summarized descriptively.

Other outcomes

  1. Participant preference (A vs B questionnaire) will be assessed after completion of both self fit response methods.

    Time frame: Day 1

    The first exploratory objective is to evaluate participant preference between the two RH210 self-test response methods.

    Participant preference will be assessed after completion of both RH210 response methods. The endpoint will include:

    • proportion of participants preferring the detection response method;
    • proportion preferring the audibility-release response method;
    • proportion reporting no preference;
    • reasons for preference, where collected. No formal hypothesis is proposed. Results will be summarized descriptively.
  2. Compare the practical performance of the two RH210 self-test response methods using NAL checklist.

    Time frame: Day 1

    Exploratory endpoints will include, for each response method:

    • completion rate;
    • invalid or unusable test rate;
    • missing frequency-specific data rate;
    • test duration;
    • participant-reported ease of use;
    • observed difficulty or need for clarification;
    • repeatability or response consistency, where repeat data are available.

    No formal hypothesis is proposed. Results will be summarized descriptively.

Study contacts

Contact information is provided by the study sponsor or research team.

Marisa Poulos, Master of Audiology

CONTACT

[email protected]

+61 2 9412 6872

Sanna Hou, Master of Audiology

CONTACT

[email protected]

+61 2 9412 6872

Sponsors and collaborators

Lead sponsor

Rehear Audiology Company LTD

Industry

Collaborators

  • Global Edge Medtech Consulting
  • National Acoustic Laboratories

Registry information

Official study title

Clinical Evaluation of Two Rehear RH210 Self-Assessment Methods for Generating NAL-R-Based Prescribed Gain Compared With Conventional Audiometry in Adults With Perceived Mild-to-Moderate Hearing Loss

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jul 31, 2026
Registry last updated
Jul 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.